Anteris Technologies higher as DurAVR™ transcatheter heart valve system receives FDA tick for early feasibility study – Proactive Investors USA
Related Articles
Anteris Technologies completes treatment of second cohort in first-in-human study for transcatheter heart valve system – Proactive Investors Australia
11:42 Tue 31 May 2022Anteris Technologies cements position as serious player in TAVR market with in-vivo demonstration of ComASUR™ Transfemoral Delivery System “We are thrilled…
Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System – Yahoo Finance
SUZHOU, China, Nov. 25, 2022 /PRNewswire/ — inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully…
Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System – BioSpace
Skip to main content Published: Nov 25, 2022 SUZHOU, China, Nov. 25, 2022 /PRNewswire/ — inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical…
Proactive news headlines including Anteris Technologies, Queensland Pacific Metals, Hawsons Iron and International Graphite – Yahoo Finance
Sydney, Nov. 28, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following…
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies – Longview News-Journal
Sunny skies. High 94F. Winds light and variable.. Clear. Low 72F. Winds light and variable. Updated: September 18, 2022 @ 2:03 amAbbott Logo (PRNewsFoto/Abbott) (PRNewsFoto/Abbott)…